|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DOK4 |
Gene summary for DOK4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DOK4 | Gene ID | 55715 |
| Gene name | docking protein 4 | |
| Gene Alias | IRS-5 | |
| Cytomap | 16q21 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | H3BQ19 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55715 | DOK4 | P1T-E | Human | Esophagus | ESCC | 1.66e-03 | 1.72e-01 | 0.0875 |
| 55715 | DOK4 | P2T-E | Human | Esophagus | ESCC | 5.36e-08 | 1.57e-01 | 0.1177 |
| 55715 | DOK4 | P4T-E | Human | Esophagus | ESCC | 1.04e-11 | 2.84e-01 | 0.1323 |
| 55715 | DOK4 | P8T-E | Human | Esophagus | ESCC | 3.65e-10 | 1.39e-01 | 0.0889 |
| 55715 | DOK4 | P11T-E | Human | Esophagus | ESCC | 4.74e-07 | 3.17e-01 | 0.1426 |
| 55715 | DOK4 | P12T-E | Human | Esophagus | ESCC | 2.55e-08 | 1.41e-01 | 0.1122 |
| 55715 | DOK4 | P15T-E | Human | Esophagus | ESCC | 2.66e-05 | 1.20e-01 | 0.1149 |
| 55715 | DOK4 | P16T-E | Human | Esophagus | ESCC | 1.97e-10 | 1.74e-01 | 0.1153 |
| 55715 | DOK4 | P17T-E | Human | Esophagus | ESCC | 3.85e-02 | 1.59e-01 | 0.1278 |
| 55715 | DOK4 | P19T-E | Human | Esophagus | ESCC | 2.07e-02 | 2.18e-01 | 0.1662 |
| 55715 | DOK4 | P20T-E | Human | Esophagus | ESCC | 2.63e-14 | 3.15e-01 | 0.1124 |
| 55715 | DOK4 | P21T-E | Human | Esophagus | ESCC | 3.28e-09 | 2.18e-01 | 0.1617 |
| 55715 | DOK4 | P22T-E | Human | Esophagus | ESCC | 9.42e-08 | 2.14e-01 | 0.1236 |
| 55715 | DOK4 | P23T-E | Human | Esophagus | ESCC | 1.99e-03 | 1.61e-01 | 0.108 |
| 55715 | DOK4 | P24T-E | Human | Esophagus | ESCC | 2.88e-09 | 1.44e-01 | 0.1287 |
| 55715 | DOK4 | P26T-E | Human | Esophagus | ESCC | 5.17e-09 | 1.89e-01 | 0.1276 |
| 55715 | DOK4 | P27T-E | Human | Esophagus | ESCC | 4.58e-04 | 1.13e-01 | 0.1055 |
| 55715 | DOK4 | P28T-E | Human | Esophagus | ESCC | 8.87e-08 | 1.66e-01 | 0.1149 |
| 55715 | DOK4 | P30T-E | Human | Esophagus | ESCC | 9.13e-09 | 2.75e-01 | 0.137 |
| 55715 | DOK4 | P31T-E | Human | Esophagus | ESCC | 1.71e-14 | 2.73e-01 | 0.1251 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00434107 | Oral cavity | OSCC | positive regulation of MAPK cascade | 213/7305 | 480/18723 | 8.71e-03 | 3.16e-02 | 213 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DOK4 | SNV | Missense_Mutation | c.638N>A | p.Thr213Lys | p.T213K | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| DOK4 | insertion | Nonsense_Mutation | novel | c.786_787insGGGATAATCAGAGCTTGAGGCTGGCACTCTGACTGCTGGCTTTTC | p.Thr262_Thr263insGlyIleIleArgAlaTerGlyTrpHisSerAspCysTrpLeuPhe | p.T262_T263insGIIRA*GWHSDCWLF | protein_coding | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| DOK4 | SNV | Missense_Mutation | rs755062671 | c.283G>A | p.Asp95Asn | p.D95N | protein_coding | deleterious(0) | possibly_damaging(0.747) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| DOK4 | SNV | Missense_Mutation | novel | c.691N>A | p.Ala231Thr | p.A231T | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A8QF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| DOK4 | SNV | Missense_Mutation | rs147737584 | c.755N>T | p.Thr252Met | p.T252M | protein_coding | deleterious(0.02) | benign(0.062) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DOK4 | SNV | Missense_Mutation | c.190N>G | p.Asn64Asp | p.N64D | protein_coding | tolerated(0.08) | possibly_damaging(0.759) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| DOK4 | SNV | Missense_Mutation | rs757770307 | c.665G>A | p.Arg222His | p.R222H | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| DOK4 | SNV | Missense_Mutation | c.133N>C | p.Tyr45His | p.Y45H | protein_coding | deleterious(0) | probably_damaging(0.926) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| DOK4 | SNV | Missense_Mutation | rs755411412 | c.577N>T | p.Arg193Cys | p.R193C | protein_coding | deleterious(0.03) | benign(0.221) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| DOK4 | SNV | Missense_Mutation | c.752G>A | p.Gly251Asp | p.G251D | protein_coding | tolerated(0.19) | benign(0.099) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |